# US 2016/0251406 A1 · Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251406 A1
- Document ID: US20160251406A1
- Status: Published application
- Kind: A1
- Application number: 15/031,435
- Filed: 2014-10-22
- Published: 2016-09-01
- Earliest claimed: 2013-10-23
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Applicants: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
- Inventors: Jeffrey SCHLOM; Kwong-Yok TSANG
- Web page: https://patentgrep.com/patent/US20160251406A1

## CPC

- C07K 14/4727: {Mucins, e.g. human intestinal mucin}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/195: {Chemokines, e.g. RANTES}
- A61K 38/20: Interleukins [IL]
- A61K 38/217: {IFN-gamma}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4257: {Mucins, e.g. MUC-1}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- C07K 14/82: Translation products from oncogenes
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- A61K 2239/31: characterized by the route of administration
- C07K 2319/00: Fusion polypeptide
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2710/24171: Demonstrated in vivo effect
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

## Claims

### Claim 1

A peptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide has no more than 20 amino acid residues.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein the peptide consists of SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 4 (depends on 1)

A nucleic acid encoding the peptide of claim 1.

### Claim 5 (depends on 4)

A vector comprising the nucleic acid of claim 4.

### Claim 6 (depends on 1)

A cell comprising (i) one or more of the peptides of claim 1, (ii) one or more nucleic acids that encode the one or more peptides, or (iii) one or more vectors comprising the one or more nucleic acids.

### Claim at position 7

-8. (canceled)

### Claim 9 (depends on 1)

A composition comprising:
(a) one or more of (i) the peptide of claim 1, (ii) a nucleic acid encoding the peptide, (iii) a vector comprising the nucleic acid, or (iv) a cell comprising (i), (ii), or (iii), and
(b) a pharmaceutically acceptable carrier.

### Claim 10 (depends on 10)

The composition of claim 10, further comprising an immunostimulatory/regulatory molecule.

### Claim at position 10

-19. (canceled)

### Claim 20 (depends on 9)

A method of enhancing an immune response against a MUC1-expressing cancer in a subject comprising administering a therapeutically effective amount of the composition of claim 9 to the subject, wherein the immune response in the subject is enhanced.

### Claim 21 (depends on 9)

A method of inhibiting a MUC1-expressing cancer in a subject comprising:
(a) obtaining lymphocytes from the subject,
(b) stimulating the lymphocytes with the composition of claim 9 to generate cytotoxic T lymphocytes ex vivo, and
(c) administering the cytotoxic T lymphocytes to the subject, wherein the MUC1-expressing cancer in the subject is inhibited.

### Claim 22 (depends on 9)

A method for inhibiting a MUC1-expressing cancer in a subject comprising:
(a) obtaining dendritic cells from the subject,
(b) treating the dendritic cells with the composition of claim 9 ex vivo, and
(c) administering the treated dendritic cells to the subject,
wherein the MUC1-expressing cancer in the subject is inhibited.

### Claim 23 (depends on 9)

A method for inhibiting a MUC1-expressing cancer in a subject comprising:
(a) obtaining peripheral blood mononuclear cells (PBMCs) from the subject,
(b) isolating dendritic cells from the PBMCs,
(c) treating the dendritic cells with the composition of claim 9 ex vivo,
(d) activating the PBMCs with the treated dendritic cells ex vivo, and
(e) administering the activated PBMCs to the subject,
wherein the MUC1-expressing cancer in the subject is inhibited.

### Claim 24 (depends on 9)

A method for inhibiting a MUC1-expressing cancer in a subject comprising:
(a) obtaining peripheral blood mononuclear cells (PBMCs) from the subject,
(b) isolating dendritic cells from the PBMCs,
(c) treating the dendritic cells with the composition of claim 9 ex vivo,
(d) activating the PBMCs with the treated dendritic cells ex vivo,
(e) isolating T lymphocytes from the activated PBMCs ex vivo, and
(f) administering the isolated T lymphocytes to the subject,
wherein the MUC1-expressing cancer in the subject is inhibited.

### Claim 25

(canceled)

### Claim 26

A yeast-MUC1 immunotherapeutic composition, wherein the immunotherapeutic composition comprises:
(a) a yeast vehicle; and
(b) a fusion protein comprising at least one mucin-1 (MUC1) antigen, wherein the MUC1 antigen comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 27

(canceled)

### Claim 28

A yeast-MUC1 immunotherapeutic composition, wherein the immunotherapeutic composition comprises:
(a) a yeast vehicle; and
(b) a fusion protein comprising at least one MUC1 antigen, wherein the MUC1 antigen comprises an amino acid sequence that is at least 80% identical to (i) SEQ ID NO:
16, (ii) positions 92-566 of SEQ ID NO: 16, or (iii) a corresponding sequence from a different MUC1 protein, and wherein the MUC1 antigen comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim at position 20

-33. (canceled)

### Claim 34

A yeast-MUC1 immunotherapeutic composition, wherein the immunotherapeutic composition comprises:
(a) a yeast vehicle; and
(b) a fusion protein comprising at least one MUC1 antigen, wherein the MUC1 antigen has an amino acid sequence that differs from an amino acid sequence of a wild-type MUC1 protein by at least one amino acid substitution at a sequence position, with respect to a wild-type MUC1 amino acid sequence, selected from: T422, P430, T431, 5462, and A470.

### Claim at position 22

-36. (canceled)

### Claim 37 (depends on 34)

The Yeast-MUC1 immunotherapeutic composition of claim 34, wherein the MUC1 antigen further comprises a substitution of the amino acid at the position C404 with respect to a wild-type MUC1 amino acid sequence.

### Claim 38 (depends on 34)

The Yeast-MUC1 immunotherapeutic composition of claim 34, wherein the amino acid substitutions, with respect to SEQ ID NO: 14, are selected from: T93L, A161Y, P162L, G169V, S170Y, T171L, A392Y, C404A, C406V, T422K, P430A, T431L, T444L, D445F, and S460Y.

### Claim 39 (depends on 26)

The Yeast-MUC1 immunotherapeutic composition of claim 26, wherein the yeast vehicle is a whole yeast.

### Claim 40 (depends on 26)

The Yeast-MUC1 immunotherapeutic composition of claim 26, wherein the fusion protein has been expressed by the yeast.

### Claim 41 (depends on 26)

The Yeast-MUC1 immunotherapeutic composition of claim 26, wherein the yeast vehicle has been heat-inactivated.

### Claim 42 (depends on 26)

The Yeast-MUC1 immunotherapeutic composition of claim 26, wherein the yeast vehicle is from Saccharomyces cerevisiae.

### Claim 43 (depends on 26)

The Yeast-MUC1 immunotherapeutic composition of claim 26, wherein the immunotherapeutic composition has been produced by culturing a whole yeast expressing the MUC1 antigen in a medium that was maintained at a pH level of between 5.5 and 8.

### Claim 44 (depends on 26)

A method of reducing tumor burden, inhibiting tumor growth, and/or increasing survival of an individual who has a cancer that expresses MUC1, comprising administering to the individual the Yeast-MUC1 immunotherapeutic composition of claim 26.

### Claim 45 (depends on 44)

The method of claim 44, wherein MUC1 expression is detected in the individual's cancer at the time the composition is first administered.

### Claim 46 (depends on 44)

The method of claim 44, wherein the individual is being treated or has been treated with at least one additional therapy for cancer.

### Claim 47

(canceled)

### Claim 48 (depends on 26)

A method of preventing or delaying the onset of a MUC1-expressing cancer, comprising administering to an individual the Yeast-MUC1 immunotherapeutic composition of claim 26.

### Claim 49 (depends on 48)

The method of claim 48, wherein cancer has not been detected in the individual.

### Claim 50 (depends on 49)

The method of claim 49, wherein the individual is at high risk for developing cancer.

### Claim 51 (depends on 44)

The method of claim 44, wherein the cancer is of epithelial cell origin.

### Claim 52 (depends on 44)

The method of claim 44, wherein the cancer is selected from the group consisting of: breast cancer, small intestine cancer, stomach cancer, pancreatic cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular cancer, lung cancer, colon cancer, prostate cancer, melanoma, esophageal cancer, multiple myelogenous leukemia (MML), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), Burkitt's lymphoma, Hodgkin's lymphoma, cancers of secretory tissues, and metastatic cancers thereof.

### Claim at position 39

-58. (canceled)

### Claim 59

A MUC1 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 60 (depends on 1)

A method of inducing an immune response against a MUC1-expressing cancer in a subject comprising:
(a) administering to the subject a first poxviral vector comprising a nucleic acid encoding the peptide of claim 1; and
(b) administering to the subject a second poxviral vector comprising a nucleic acid encoding the peptide of claim 1,
thereby inducing an immune response against a MUC1-expressing cancer in the subject.

### Claim 61 (depends on 59)

A method of inducing an immune response against a MUC1-expressing cancer in a subject comprising:
(a) administering to the subject a first poxviral vector comprising a nucleic acid encoding the MUC1 protein of claim 59; and
(b) administering to the subject a second poxviral vector comprising a nucleic acid encoding the MUC1 protein of claim 59,
thereby inducing an immune response against a MUC1-expressing cancer in the subject.

### Claim 62 (depends on 60)

The method of claim 60, wherein the first and second poxviral vectors further comprise a nucleic acid encoding carcinoembryonic antigen (CEA).

### Claim 63 (depends on 60)

The method of claim 60, wherein the first and second poxviral vectors further comprise a nucleic acid encoding one or more co-stimulatory molecules.

### Claim 64 (depends on 63)

The method of claim 63, wherein the one or more co-stimulatory molecules are selected from B7.1, ICAM-1, and LFA-3.

### Claim 65 (depends on 60)

The method of claim 60, wherein the first poxviral vector is a vaccinia virus and the second poxviral vector is a fowlpox virus.

### Claim 66 (depends on 60)

The method of claim 60, wherein the first poxviral vector is a modified Vaccinia Ankara (MVA) virus and the second poxviral vector is a fowlpox virus.

### Claim 67 (depends on 66)

The method of claim 66, wherein the MVA virus is MVA-BN.

### Claim 68 (depends on 60)

The method of claim 60, wherein the first and second poxviral vectors are administered to the subject in a prime-boost protocol.
